{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:24:39Z","timestamp":1787793879141,"version":"build-2784847793"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Checkpoint inhibitor therapy is widely known to cause a number of immune-related adverse events. One rare adverse effect that is emerging is eosinophilic fasciitis, a fibrosing disorder causing inflammatory infiltration of subcutaneous fascia. It is characterized clinically by edema and subsequent induration and tightening of the skin and subcutaneous tissues. The condition is rare, yet at our institutions we have seen four cases in the past 3\u2009years. We describe our 4 cases and review 11 other cases reported in the literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case Presentation<\/jats:title>\n                  <jats:p>We present four cases of eosinophilic fasciitis following treatment with programmed cell death protein 1 or programmed cell death-ligand 1 blockade. All patients had extremity involvement with characteristic skin changes ranging from peripheral edema to induration, tightening, and joint limitation. The patients had varying degrees of peripheral eosinophilia. In two of our patients, the diagnosis was made by full-thickness skin biopsy showing lymphocytic infiltration of the subcutaneous fascia, with CD4+ T cells predominating in one case and CD8+ T cells in the other. In the other two cases, the diagnosis was made on the basis of characteristic imaging findings in the context of clinical features consistent with the diagnosis. All four patients were treated with glucocorticoids with varying degrees of success; immunotherapy had to be discontinued in all four. Patients with advanced melanoma who experienced this adverse effect had either a partial response or a complete response to therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Eosinophilic fasciitis can occur as a result of checkpoint inhibitor therapy. Although a tissue diagnosis is the gold standard, imaging studies may facilitate the diagnosis in the presence of consistent clinical features, but a degree of suspicion is key to recognizing the condition early. Therapy requires a collaborative approach by oncology, rheumatology, and dermatology; physical therapy is an important adjunct in treatment. For advanced melanoma, it may be a good prognostic indicator.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0508","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:32:17Z","timestamp":1571167937000},"page":"140-149","source":"Crossref","is-referenced-by-count":64,"title":["Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature"],"prefix":"10.1093","volume":"25","author":[{"given":"Karmela Kim","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Medicine, Hospital for Special Surgery, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Magro","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Rudin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Rotemberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lezcano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Carrino","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hospital for Special Surgery, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hospital for Special Surgery, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Postow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlyn","family":"Apollo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne R.","family":"Bass","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hospital for Special Surgery, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2021122510033368000_R1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2021122510033368000_R2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122510033368000_R3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021122510033368000_R4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","article-title":"Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases","volume":"17","author":"Lakhanpal","year":"1988","journal-title":"Semin Arthritis Rheum"},{"key":"2021122510033368000_R5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.berh.2012.08.001","article-title":"Eosinophilic fasciitis (Shulman disease)","volume":"26","author":"Lebeaux","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2021122510033368000_R6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clindermatol.2018.04.006","article-title":"Eosinophilic fasciitis: Current concepts","volume":"36","author":"Fett","year":"2018","journal-title":"Clin Dermatol"},{"key":"2021122510033368000_R7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","article-title":"Diagnosis and classification of eosinophilic fasciitis","volume":"13","author":"Pinal-Fernandez","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2021122510033368000_R8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Cancer immunology miniatures eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2021122510033368000_R9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2021122510033368000_R10","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.12836","article-title":"Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab","volume":"59","author":"Andr\u00e9s-Lencina","year":"2018","journal-title":"Australas J Dermatol"},{"key":"2021122510033368000_R11","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jtho.2018.09.016","article-title":"An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab","volume":"14","author":"Le Tallec","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2021122510033368000_R12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/rheumatology\/kez164","article-title":"Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response","volume":"58","author":"Toussaint","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2021122510033368000_R13","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/imj.14126","article-title":"Immune checkpoint inhibitor-induced lymphocytic fasciitis","volume":"48","author":"Rischin","year":"2018","journal-title":"Intern Med J"},{"key":"2021122510033368000_R14","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223249","article-title":"Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab","author":"Parker","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2021122510033368000_R15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/rheumatology\/kex369","article-title":"Immune checkpoint inhibitor-induced myo-fasciitis","volume":"56","author":"Daoussis","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2021122510033368000_R16","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2021122510033368000_R17","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"Am J Roentgenol"},{"key":"2021122510033368000_R18","first-page":"1179","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021122510033368000_R19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","article-title":"Paraneoplastic syndromes in rheumatology","volume":"10","author":"Manger","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2021122510033368000_R20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.hemonc.2013.12.003","article-title":"Eosinophilic fasciitis as a paraneoplastic syndrome, a case report and review of the literature","volume":"7","author":"Haddad","year":"2014","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2021122510033368000_R21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous manifestations of scleroderma and scleroderma-like disorders: A comprehensive review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021122510033368000_R22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-017-0700-6","article-title":"Eosinophilic fasciitis: An updated review on diagnosis and treatment","volume":"19","author":"Mazori","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"2021122510033368000_R23","first-page":"1811","article-title":"In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis","volume":"30","author":"Toquet","year":"2003","journal-title":"J Rheumatol"},{"key":"2021122510033368000_R24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"2021122510033368000_R25","first-page":"461","article-title":"Immune checkpoint inhibitors and neuromuscular adverse events [in Japanese]","volume":"70","author":"Suzuki","year":"2018","journal-title":"Brain Nerve"},{"key":"2021122510033368000_R26","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122510033368000_R27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40425-017-0258-x","article-title":"Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment","volume":"5","author":"John","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122510033368000_R28","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0190-9622(03)00447-X","article-title":"Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: Increased production of interleukin 5 and inhibition by interferon alfa","volume":"49","author":"French","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2021122510033368000_R29","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","article-title":"Opposing roles of eosinophils in cancer","volume":"68","author":"Simon","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2021122510033368000_R30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"2021122510033368000_R31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2012","journal-title":"J Immunother"},{"key":"2021122510033368000_R32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ai.2018.03.001","article-title":"Eosinophil development, disease involvement, and therapeutic suppression","volume":"138","author":"Fulkerson","year":"2018","journal-title":"Adv Immunol"},{"key":"2021122510033368000_R33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat Immunol"},{"key":"2021122510033368000_R34","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","article-title":"Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510033368000_R35","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2021122510033368000_R36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122510033368000_R37","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122510033368000_R38","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Personalized medicine and imaging myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"2021122510033368000_R39","doi-asserted-by":"crossref","first-page":"9096a","DOI":"10.1200\/jco.2014.32.15_suppl.9096","article-title":"Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab","volume":"32","author":"Schindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510033368000_R40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122510033368000_R41","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510033368000_R42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamadermatol.2015.3648","article-title":"Epidemiology and treatment of eosinophilic fasciitis: An analysis of 63 patients from 3 tertiary care centers","volume":"152","author":"Wright","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2021122510033368000_R43","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/ker366","article-title":"Eosinophilic fasciitis (Shulman disease): New insights into the therapeutic management from a series of 34 patients","volume":"51","author":"Lebeaux","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021122510033368000_R44","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamadermatol.2016.2873","article-title":"High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis","volume":"152","author":"Mertens","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2021122510033368000_R45","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2021122510033368000_R46","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/140\/41920228\/oncolo_25_2_140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/2\/140\/41920228\/oncolo_25_2_140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:06:03Z","timestamp":1640426763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/2\/140\/6443484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,15]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0508","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,10,15]]}}}